COLLEGIUM PHARMACEUTICAL,INC. (NASDAQ:COLL) Files An 8-K Termination of a Material Definitive Agreement

ME Staff 8-k
-
0

COLLEGIUM PHARMACEUTICAL,INC. (NASDAQ:COLL) Files An 8-K Termination of a Material Definitive Agreement
Item 1.02 Termination of a Material Definitive Agreement.

On December8, 2017, Collegium Pharmaceutical,Inc. (the “Company”), after a review of its product portfolio in connection with its execution of a license agreement with Depomed to which it expects to license the right to commercialize Nucynta® (tapentadol) Immediate Release and Nucynta® ER (tapentadol) in the U.S., provided written notice to BioDelivery Sciences International,Inc. (“BDSI”) of termination of the License and Development Agreement dated May11, 2016 (the “License Agreement”), which termination will be effective to the terms of such agreement on March8, 2018. Upon such termination of the License Agreement, the Company’s rights to develop and commercialize Onsolis® (fentanyl buccal soluble film), a Transmucosal Immediate-Release Fentanyl film indicated for the management of breakthrough pain in certain cancer patients, will revert to BDSI. A summary of the material terms of the License Agreement was included in the Company’s Current Report on Form8-K filed on May12, 2016, which is incorporated herein by reference and is qualified in its entirety by reference to the full text of the License Agreement (filed as an exhibit to our Quarterly Report on Form10-Q filed with the Commission on August11, 2016).


About COLLEGIUM PHARMACEUTICAL,INC. (NASDAQ:COLL)

Collegium Pharmaceutical, Inc. is a specialty pharmaceutical company. The Company focuses on developing and commercializing abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases. The Company’s lead product candidate, Xtampza ER (Xtampza), is an abuse-deterrent, extended-release, oral formulation of oxycodone, a prescribed opioid medication. The Company’s DETERx platform technology is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods of abuse and tampering, including chewing, crushing and/or dissolving, and then taking them orally or snorting or injecting them. It also focuses on development program for COL 195, an abuse deterrent, extended release hydrocodone for the treatment of chronic pain. It is focusing on COL 171, a preclinical DETERx extended release, abuse deterrent methylphenidate formulation for the treatment of ADHD.